Cold Plasma plus Concomitant and Adjuvant Therapies for Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 2224

Special Issue Editors


E-Mail Website
Guest Editor
Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Interests: cold plasma; cancer; free radicals; cancer treatments; plasma medicine; autophagy

E-Mail Website
Guest Editor
Department of Mechanical & Aerospace Engineering, The George Washington University, Washington, DC 20052, USA
Interests: cold plasma; cancer; free radicals; cancer treatments; plasma medicine; plasma physics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cold plasma is a novel, non-thermal technology that generates reactive oxygen and nitrogen species, as well as other biologically active molecules, which have been shown to induce cancer cell death while sparing normal cells. Although cold plasma has shown promising results as an anti-cancer therapy, its efficacy as a standalone treatment is limited. Therefore, this Special Issue explores the use of cold plasma in combination with concomitant and adjuvant therapies for cancer treatment.

Concomitant therapies refer to the use of cold plasma alongside conventional cancer treatments, such as chemotherapy and radiation therapy. Studies have demonstrated that using cold plasma alongside chemotherapy or radiation therapy enhances their efficacy by sensitizing cancer cells to the treatment, thereby increasing cell death. On the other hand, adjuvant therapies refer to the use of cold plasma alongside complementary therapies, such as immunotherapy and photodynamic therapy, which have shown promising results in cancer treatment. These combinations can also enhance the immune system's response to cancer and improve the effectiveness of the therapy.

The evidence from the latest research demonstrate the potential of cold plasma to act synergistically with concomitant and adjuvant therapies, which could lead to more effective and less toxic cancer treatments. However, further research is needed to optimize the use of cold plasma in combination with other therapies and to evaluate its potential as a standalone treatment for cancer. The main focus of this Issue aims to publish papers on different kinds of cancers treated with cold plasma with/without a combination of another agent. Overall, this Special Issue highlights the potential of cold plasma as an effective and complementary therapy for cancer treatment.

Dr. Manish Adhikari
Prof. Dr. Michael Keidar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cold plasma
  • cancer
  • free radicals
  • cancer treatments
  • plasma medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 4962 KiB  
Article
Combined Effect of Plasma-Activated Water and Topotecan in Glioblastoma Cells
by Beatriz Pinheiro Lopes, Liam O’Neill, Paula Bourke and Daniela Boehm
Cancers 2023, 15(19), 4858; https://doi.org/10.3390/cancers15194858 - 5 Oct 2023
Cited by 4 | Viewed by 1601
Abstract
The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding [...] Read more.
The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding GBM treatment, the final outcome is still very poor, making it necessary to develop new therapeutic approaches. Cold atmospheric plasma (CAP) as well as plasma-activated liquids (PAL) are being studied as new possible approaches against cancer. The anticancer activity of PAL such as “plasma-activated water” (PAW) is dependent on the reactive chemical compounds present in the solution. Possible combinatory effects with conventional therapies, such as chemotherapeutics, may expand the potential of PAL for cancer treatment. We aim to explore the therapeutic properties of a combination of PAW and topotecan (TPT), an antineoplastic agent with major cytotoxic effects during the S phase of the cell cycle, on a GBM cancer cell line (U-251mg). Combined treatments with PAW and TPT showed a reduction in the metabolic activity and cell mass, an increase in apoptotic cell death and a reduction in the long-term survival. Single applications of PAW+TPT treatments showed a cytotoxic effect in the short term and an antiproliferative effect in the long term, warranting future exploration of combining PAW with chemotherapeutic agents as new therapeutic approaches. Full article
Show Figures

Graphical abstract

Back to TopTop